Intellia Therapeutics Inc. (NTLA) is making significant strides in the gene editing space as it advances its lead candidate, lonvoguran ziclumeran (lonvo-z), toward pivotal clinical milestones.
Highlights:
• Phase 3 HAELO enrollment completed in 9 months; ~50% from the U.S.• Topline data expected in H1 2026• BLA submission planned for H2 2026; potential U.S. launch in H1 2027• Additional Phase 1/2 data to be presented in Q4 2025
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.